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Hyperphosphorylation of tau is a characteristic of Alzhe-
imer's disease (AD). Our group has established a model
for tau hyperphosphorylation by mutating 10 residues
from Ser/Thr to Glu to simulate the negative charge of
phosphorylated residues ("pseudohyperphosphorylated
(PHP)-tau").
In order to analyze temporal and spatial effects of hyper-
phosphorylation of tau in a systemic context, we have
established transgenic mouse lines that express human
wild-type (wt)- or PHP-tau under the control of the Cam-
KIIalpha-promoter that leads to a forebrain specific mod-
erate expression in neurons, i.e. the region where also tau-
pathology in AD is abundant.
For the evaluation of tau-induced changes in the trans-
genic mice, we quantified spine densities in the neocortex
and hippocampus of transgenic mice. The spine densitiy
was significantly increased in PHP-tau compared to wt-tau
expressing mice. It is known that AD is associated with
aberrant pre- and postsynaptic sprouting. Axonal sprout-
ing is also observed in transgenic mice expressing mutated
amyloid precursor protein (APP), which suggests that
Abeta plays a significant role in this process.
We deduce from our results, that (pseudo)-hyperphos-
phorylation of tau is sufficient to induce aberrant sprout-
ing in the absence of Abeta. Analyses whether this
sprouting is induced by pre- or postsynaptic changes and
if functionally active synapses are formed are in progress.
It will be interesting to determine if stabilization of these
newly formed synapses slows or – in contrary – accelerates
the progression of the disease.
Sprouting as observed in our PHP-tau expressing mice is
part of neuronal differentiation. One family of enzymes
that is involved in cell differentiation are mitogen-acit-
vated protein kinases (MAPK). Western blot analysis was
performed with brain lysates from transgenic mice to
check whether PHP-tau induced sprouting is associated
with MAPK activation. In fact, we also observed an
increased activation of the MAPK ERK1/2 evident by
phosphorylation of the residues Thr202 and Tyr204.
ERK1/2 is also known to phosphorylate tau at sites char-
acteristic for AD. Our results suggest the presence of a
vicious circle by which (pseudo)-hyperphosphorylated
tau activates ERK1/2 which in turn phosphorylates tau.
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